Leerink analyst Mike Kratky notes that a new sub-analysis showing similar clinical benefits of AID in T2 patients regardless of their C-peptide levels, alongside increasing advocacy efforts, may help support updates to the current CMS reimbursement policy. This could lead to greater pump adoption broadly and would be most positive for tubed pumps, including Tandem Diabetes (TNDM), Medtronic (MDT) and Beta Bionics (BBNX). While the firm notes that there is no clear timeline on any potential CMS update, it believes it could happen relatively soon based on emerging clinical data and increasing advocacy efforts. If implemented, this could represent a meaningfully positive catalyst for the pump market broadly and would be particularly valuable in driving greater adoption among Type 2 patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes announces publication of 2IQP study in Diabetes Care
- Tandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold Rating
- Tandem Diabetes assumed with an Outperform at Oppenheimer
- Tandem announces Health Canada authorization for t:slim mobile application
- Tandem Diabetes price target raised to $11 from $10.35 at Citi